| Entire group | CXCR4 expression | ETAR expression | ||||
---|---|---|---|---|---|---|---|
 | (n = 153) | n (No.%) | n (No.%) | ||||
Characteristic | Â | Positive | Negative | P value | Positive | Negative | P value |
All patients | 153 | 48(31.4) | 105(68.6) | Â | 113(73.9) | 40(26.1) | Â |
Mean follow-up, months | 83.27 | 62.77 | 92.64 | Â | 79.81 | 93.05 | Â |
Age, years | Â | Â | Â | 0.049 | Â | Â | 0.741 |
≤50 | 100(65.4) | 26(26.0) | 74(74.0) |  | 73(73.0) | 27(27.0) |  |
>50 | 53(34.6) | 22(41.6) | 31(58.4) | Â | 40(75.5) | 13(24.5) | Â |
Sex | Â | Â | Â | 0.27 | Â | Â | 0.213 |
Male | 111(72.5) | 32(28.8) | 79(71.2) | Â | 85(76.6) | 26(23.4) | Â |
Female | 42(27.5) | 16(38.1) | 26(61.9) | Â | 28(66.7) | 14(33.3) | Â |
T classification a | Â | Â | Â | 0.098 | Â | Â | 0.517 |
T1-2 | 66(43.1) | 16(24.2) | 50(75.8) | Â | 47(71.2) | 19(28.8) | Â |
T3-4 | 87(56.9) | 32(36.8) | 55(63.2) | Â | 66(75.9) | 21(24.1) | Â |
N classification a | Â | Â | Â | 0.681 | Â | Â | 0.284 |
N0 | 32(20.9) | 11(34.4) | 21(65.6) | Â | 26(81.3) | 6(19.7) | Â |
N1-N3 | 121(79.1) | 37(30.6) | 84(69.4) | Â | 87(71.9) | 34(29.1) | Â |
Overall stage a | Â | Â | Â | 0.376 | Â | Â | 0.94 |
I-II | 49(32.0) | 13(26.5) | 36(73.5) | Â | 36(73.5) | 13(26.5) | Â |
III-IV | 104(68.0) | 35(33.7) | 69(66.3) | Â | 77(74.0) | 27(26.0) | Â |
Chemotherapy | Â | Â | Â | 0.394 | Â | Â | 0.362 |
Yes | 47(30.7) | 17(36.2) | 30(63.8) | Â | 37(78.7) | 10(21.3) | Â |
No | 106(69.3) | 31(29.2) | 75(70.8) | Â | 76(71.7) | 30(28.3) | Â |